目的 探讨地奥心血康软胶囊联合美托洛尔治疗不稳定型心绞痛的临床疗效。方法 选取2022年3月-2023年3月亳州市人民医院收治的106例不稳定型心绞痛患者，按随机数字表法分为对照组和治疗组，每组各53例。对照组早饭前口服琥珀酸美托洛尔缓释片，1片/次，1次/d。治疗组在对照组基础上饭后口服地奥心血康软胶囊，2粒/次，3次/d。两组疗程均为2周。观察两组的临床疗效，比较治疗前后两组心绞痛发作情况、心肌缺血时间、医学结局研究简短量表-8（SF-8）和西雅图心绞痛量表（SAQ）评分、外周血中性粒细胞与淋巴细胞比值（NLR）及血清超敏C反应蛋白（hs-CRP）、心肌肌钙蛋白I （cTnI）、N末端B型利钠肽原（NT-proBNP）水平。结果 治疗后，治疗组总有效率是92.45%，显著高于对照组的77.36%（P<0.05）。治疗后，两组心绞痛发作次数、硝酸甘油用量均显著降低，持续时间均显著缩短（P<0.05）；治疗组心绞痛发作情况改善优于对照组（P<0.05）。治疗后，两组心肌缺血时间均显著缩短（P<0.05），SF-8、SAQ评分均显著增加（P<0.05），以治疗组改善更显著（P<0.05）。治疗后，两组外周血NLR和血清hs-CRP、cTnI、NT-proBNP水平均显著下降（P<0.05）；且以治疗组显著更低（P<0.05）。结论 地奥心血康软胶囊联合美托洛尔治疗不稳定型心绞痛有较好的临床疗效，能有效控制心绞痛发作、缓解心肌缺血状态，减轻机体炎症损伤和心肌损害，患者耐受性较好，且利于病情控制及生活质量的改善，值得临床推广应用。
Objective To explore the clinical efficacy of Di'ao Xinxuekang Soft Capsules combined with metoprolol in treatment of unstable angina pectoris. Methods A total of 106 patients with unstable angina pectoris treated in Bozhou People's Hospital from March 2022 to March 2023 were selected and divided into control group and treatment group according to random number table method, with 53 cases in each group. Patients in the control group were po administered with Metoprolol Succinate Sustained-release Tablets before breakfast, 1 tablet/time, once daily. Patients in the treatment group were po administered with Di'ao Xinxuekang Soft Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, the angina attack, myocardial ischemia time, medical outcome study short scale 8 (SF-8) and Seattle Angina Scale (SAQ) scores, peripheral blood neutrophil lymphocyte ratio (NLR), serum high-sensitivity C-reactive protein (hs CRP), myocardial Troponin I (cTnI), and N-terminal pro B-type natriuretic peptide (NT-proBNP) levels were compared between the two groups before and after treatment. Results After treatment, the total effective rate of the treatment group was 92.45%, which was significantly higher than that of the control group (77.36%, P < 0.05). After treatment, the frequency of angina pectoris attacks and the dosage of nitroglycerin were significantly decreased in both groups, and the duration was significantly shortened (P < 0.05). The improvement of angina pectoris in the treatment group was better than that in the control group (P< 0.05). After treatment, myocardial ischemia time in both groups was significantly shortened (P < 0.05), and SF-8 and SAQ scores were significantly increased (P < 0.05). The improvement was more significant in the treatment group (P < 0.05). After treatment, the levels of peripheral blood NLR, serum hs-CRP, cTnI and NT-proBNP in both groups were significantly decreased (P < 0.05). It was significantly lower in the treatment group (P < 0.05). Conclusion Di'ao Xinxuekang Soft Capsules combined with metoprolol has good clinical effect in treatment of unstable angina pectoris, can effectively control the attack of angina pectoris, relieve myocardial ischemia, reduce inflammation and myocardial damage, and patients have good tolerance, and it is conducive to disease control and improvement of life quality, which is worthy of clinical promotion and application.